In this episode of Paul Talks Science, Paul Adepoju sits down with Adam Aspinall, Senior Director of Access & Product Management at Medicines for Malaria Venture (MMV). They discuss the science and strategy behind a groundbreaking new malaria drug for newborns and young children — the first of its kind. From how scientists reformulated existing treatments to meet the needs of infants, to the global regulatory pathways that made rapid approval possible, this conversation sheds light on the innovation, policy, and persistence shaping the future of malaria control.
